Partnering is an important aspect of Xerion’s business strategy. The Company has established a number of collaborations with pharmaceutical and biotech companies as well as academic institutions. Xerion pursues several partnership models:

Target Validation
Xerion collaborates with pharma and biotech companies to help assess the function of putative targets using its antibody phage display, proteomics and CALI techniques.

Drug Target/Antibody Lead Generation
Xerion uses Xstream® to identify druggable targets to support partners who wish to obtain access to novel targets in a therapeutic indication of their choice. Based on these targets, fully human antibody leads can be generated and provided to the partner.

Co-Development
Xerion uses its capabilities to generate druggable targets and therapeutic leads in cancer and cardiovascular disease for own development and partnering. As a result, Xerion can offer co-development opportunities (see pipeline for overview).

Out-Licensing
Xerion also out-licenses qualified targets and antibody leads derived from internal programs (see pipeline for overview).

For further information on collaborating with Xerion as well as on co-development and licensing opportunities, please contact:

Europe and Near East
Jenny L Ilag, Ph.D.
Chief Technology Officer
Xerion Pharmaceuticals AG
Sauerbruchstrasse 50
D-81377 Munich Germany
TEL: +29 89 86 307 0
FAX: +29 89 86 307 112
2

North America and Asia
Yukari Perrella
President
Xerion Pharmaceuticals Inc
One Broadway, Suite 600
Cambridge, MA 02142 U.S.A.
TEL: +1 217 621 7123
FAX: +1 217 621 7124
2